Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants

SARS-CoV-2 LP.8.1.1、NB.1.8.1、XFG 及相关亚型的抗体逃避和受体结合

阅读:1

Abstract

SARS-CoV-2 continues to evolve, causing waves of infections. It is critical to understand the features of the virus that explain its growth advantages. Recently, SARS-CoV-2 Omicron JN.1 subvariants KP.3.1.1 and XEC were outcompeted by LP.8.1 and LP.8.1.1. Other subvariants, including LF.7.2.1 and MC.10.1, were also under monitoring. Subsequently, NB.1.8.1 and XFG became dominant. We found that serum neutralizing antibody titers against LP.8.1, LP.8.1.1, LF.7, LF.7.2.1, and MC.10.1 were similar to XEC in 40 adults, including KP.2 monovalent mRNA vaccine recipients. NB.1.8.1 and XFG were more evasive of serum neutralization than LP.8.1.1. Neutralization by 12 monoclonal antibodies (mAbs) revealed that LP.8.1 and XFG, MC.10.1 and NB.1.8.1, and LF.7.2.1 evade different mAb classes. Lastly, the receptor-binding affinity of LP.8.1 was the highest among the tested viruses. Unlike most prior SARS-CoV-2 sublineage evolutionary trajectories, receptor-binding affinity better explained the rise of LP.8.1, while expansion of NB.1.8.1 and XFG appears correlated with enhanced antibody evasion.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。